• Built $100M+ practice from the ground up, establishing Deloite as a Tier 1 life sciences consultancy • Client portfolio: 8 of the top 10 global pharmaceutical companies with 30% improvement in retention • Team leadership: 50+ consultants across Europe, North America, Asia • Innovation: Proprietary RWE - payer negotiation framework adopted across global practice • Strategic consulting: Led major client engagement at CEGEDIM 2019), transforming RWE platform

• Founded boutique consultancy serving biotech startups to global pharma (95% client retention) • Client outcomes: 40% reduction in time - to - market, 25% improvement in market access success • Methodology: Pioneered "value - first" approach combining clinical optimization with • payer strategy • Exit strategy: Practice capabilities integrated into Deloite Global platform (2017)

• Revenue generation: $300M annual from three breakthrough vaccine launches in emerging markets • Operational excellence: 95% regulatory timeline adherence, 24 - month time - to market reduction • Market access: Negotiated government pricing agreements and international distribution partnerships

• Portfolio turnaround: 20% market share increase, 30% profitability improvement in cardiovascular franchise • Revenue impact: $75M incremental revenue within 24 months • Strategic repositioning: Patient - centric go - to - market transformation

• Market leadership: Established diagnostics company as category leader with 60% YoY growth • Market penetration: 30% market share and 95% target customer adoption in Year 1 • EU expansion: Secured region - wide market authorization and distribution network